Sale!

CJC/IPA Blend 10mg

Original price was: $80.00.Current price is: $60.00.

CJC-1295 (No DAC) + Ipamorelin Blend (5mg/5mg)

This research blend combines two potent Growth Hormone Secretagogues (GHS) that act synergistically to stimulate the pituitary gland. By pairing a GHRH (Growth Hormone Releasing Hormone) analog with a Ghrelin Mimetic, researchers can observe a more significant pulse of growth hormone than either peptide could produce alone.

Research Focus:

  • Synergistic GH Secretion: Investigating the “pulse” effect created when CJC-1295 (stimulating the GHRH receptor) and Ipamorelin (stimulating the Ghrelin receptor) are administered simultaneously.

  • Cellular Recovery & Repair: Studying the impact of increased GH pulses on musculoskeletal tissue recovery and protein synthesis.

  • Metabolic Efficiency: Evaluation of the blend’s influence on adipocyte metabolism (fat loss) and lean muscle preservation.

  • Pituitary Response: Researching long-term pituitary sensitivity without the “bleed” effect associated with DAC (Drug Affinity Complex) versions.

Composition:

  • CJC-1295 (No DAC): 5mg

  • Ipamorelin: 5mg


⚠️ STRICTLY FOR RESEARCH USE ONLY: This product is a lyophilized laboratory reagent intended for scientific research and in-vitro evaluation only. It is NOT for human consumption, injection, or any form of therapeutic use. Handling should only be performed by qualified professionals in a laboratory setting.

In stock

Description

CJC-1295 (w/o DAC) + Ipamorelin

5mg + 5mg | Research Blend
For In Vitro Research Use Only — Not for Human or Veterinary Use

Description

This research blend combines two well-characterized peptides commonly utilized in laboratory settings to investigate growth hormone secretagogue pathways.

CJC-1295 (without DAC) is a tetrasubstituted peptide analogue of growth hormone–releasing hormone (GHRH). The absence of the DAC modification results in a shorter half-life, making it suitable for studying pulsatile growth hormone release models in vitro.

Ipamorelin is a selective ghrelin receptor agonist researched for its ability to stimulate growth hormone release in vitro while demonstrating minimal interaction with prolactin or cortisol pathways.

When combined, CJC-1295 (w/o DAC) and Ipamorelin provide researchers with a complementary model system for examining GH-related signaling mechanisms and cellular responses.

Specifications

  • Form: Lyophilized powder

  • Unit Size: 10mg total per vial

    • 5mg CJC-1295 (w/o DAC)

    • 5mg Ipamorelin

  • Storage:

    • Store lyophilized at –20°C

    • After reconstitution, refrigerate at 2–8°C

    • Protect from light and moisture

Application Context

CJC-1295 (w/o DAC) + Ipamorelin is studied in vitro for potential roles in:

  • Growth hormone secretagogue pathway modeling

  • Pulsatile GH release versus extended half-life analogues

  • Ghrelin receptor agonist selectivity and activity

  • Synergistic peptide interactions in pituitary cell assays

  • Comparative peptide pharmacology research

Intended Use

This product is intended strictly for in vitro laboratory research. It is not approved for human or animal use and must not be used in food, drugs, dietary supplements, cosmetics, or veterinary applications.

Legal Disclaimer

This product and all related information have not been evaluated by the U.S. Food and Drug Administration. No claims are made regarding diagnosis, treatment, cure, or prevention of any disease.

Terms of Sale

By purchasing from Midwest Peptide, the buyer affirms they are a qualified researcher or institution purchasing for legitimate laboratory research purposes. The purchaser assumes full responsibility for proper handling, storage, and lawful use of this material. All sales are final.